The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030: By Root
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030”.”
The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:
An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019.
An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019.
Informed estimates of the annual commercial and clinical demand for cell therapies, in terms of number of cells produced and area dedicated to manufacturing.
An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
+1 (415) 800 3415